Market Research Life Sciences Market Research Pharmaceuticals Market Research Drug Discovery Market Research

Antiviral Drugs Market by Drug Type (Branded Drugs, Generic Drugs), Therapeutics (Acquired Immunodeficiency Syndrome Therapeutics, Hepatitis (B & C) Therapeutics, Herpes Therapeutics), End Use - Global Forecast 2024-2030

Best Price Guarantee Length Publisher Published Date SKU
from $4,749 180 Pages 360iResearch January, 2024 IRE18418430
Best Price Guarantee
Price from $4,749
Length 180 Pages
Publisher 360iResearch
Published Date January, 2024
SKU IRE18418430

Antiviral Drugs Market by Drug Type (Branded Drugs, Generic Drugs), Therapeutics (Acquired Immunodeficiency Syndrome Therapeutics, Hepatitis (B & C) Therapeutics, Herpes Therapeutics), End Use - Global Forecast 2024-2030


The Antiviral Drugs Market size was estimated at USD 56.22 billion in 2023 and expected to reach USD 59.84 billion in 2024, at a CAGR 6.54% to reach USD 87.61 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antiviral Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antiviral Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antiviral Drugs Market, highlighting leading vendors and their innovative profiles. These include Abacus Bioscience Inc., Abbott Laboratories, AbbVie Inc., Antiva Biosciences, Inc., AstraZeneca PLC, Aurobindo Pharma, Bristol-Myers Squibb Company, Chimerix Inc., Cipla Limited, Dr. Reddy’s Laboratories Ltd., ENYO Pharma SA, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., and Novartis AG.

Market Segmentation & Coverage

This research report categorizes the Antiviral Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Type

Branded Drugs
  • Generic Drugs
  • Therapeutics

    Acquired Immunodeficiency Syndrome Therapeutics
  • Hepatitis (B & C) Therapeutics
  • Herpes Therapeutics
  • Influenza Therapeutics
  • Pneumonia
  • End Use

    Ambulatory Surgical Centres
  • Clinics
  • Hospitals
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Antiviral Drugs Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antiviral Drugs Market?
    3. What are the technology trends and regulatory frameworks in the Antiviral Drugs Market?
    4. What is the market share of the leading vendors in the Antiviral Drugs Market?
    5. Which modes and strategic moves are suitable for entering the Antiviral Drugs Market?


    Note: PDF & Excel + Online Access - 1 Year


    • 1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Antiviral Drugs Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Growing occurrence of viral diseases such as HIV, hepatitis, and influenza
    5.1.1.2. Rising government and private sector expenditure in the development of antiviral drugs
    5.1.1.3. Growing number of antiviral programs and campaigns to increase customer awareness
    5.1.2. Restraints
    5.1.2.1. High cost of antiviral drug treatment and concerns of patent expiration
    5.1.3. Opportunities
    5.1.3.1. Research and development in the production of vaccines for numerous viral infections and diseases
    5.1.3.2. Extensive formulations to develop HIV vaccines
    5.1.4. Challenges
    5.1.4.1. Prevalence of alternative therapy such as homeopathy
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Antiviral Drugs Market, by Drug Type
    6.1. Introduction
    6.2. Branded Drugs
    6.3. Generic Drugs
    7. Antiviral Drugs Market, by Therapeutics
    7.1. Introduction
    7.2. Acquired Immunodeficiency Syndrome Therapeutics
    7.3. Hepatitis (B & C) Therapeutics
    7.4. Herpes Therapeutics
    7.5. Influenza Therapeutics
    7.6. Pneumonia
    8. Antiviral Drugs Market, by End Use
    8.1. Introduction
    8.2. Ambulatory Surgical Centres
    8.3. Clinics
    8.4. Hospitals
    9. Americas Antiviral Drugs Market
    9.1. Introduction
    9.2. Argentina
    9.3. Brazil
    9.4. Canada
    9.5. Mexico
    9.6. United States
    10. Asia-Pacific Antiviral Drugs Market
    10.1. Introduction
    10.2. Australia
    10.3. China
    10.4. India
    10.5. Indonesia
    10.6. Japan
    10.7. Malaysia
    10.8. Philippines
    10.9. Singapore
    10.10. South Korea
    10.11. Taiwan
    10.12. Thailand
    10.13. Vietnam
    11. Europe, Middle East & Africa Antiviral Drugs Market
    11.1. Introduction
    11.2. Denmark
    11.3. Egypt
    11.4. Finland
    11.5. France
    11.6. Germany
    11.7. Israel
    11.8. Italy
    11.9. Netherlands
    11.10. Nigeria
    11.11. Norway
    11.12. Poland
    11.13. Qatar
    11.14. Russia
    11.15. Saudi Arabia
    11.16. South Africa
    11.17. Spain
    11.18. Sweden
    11.19. Switzerland
    11.20. Turkey
    11.21. United Arab Emirates
    11.22. United Kingdom
    12. Competitive Landscape
    12.1. FPNV Positioning Matrix
    12.2. Market Share Analysis, By Key Player
    12.3. Competitive Scenario Analysis, By Key Player
    13. Competitive Portfolio
    13.1. Key Company Profiles
    13.1.1. Abacus Bioscience Inc.
    13.1.2. Abbott Laboratories
    13.1.3. AbbVie Inc.
    13.1.4. Antiva Biosciences, Inc.
    13.1.5. AstraZeneca PLC
    13.1.6. Aurobindo Pharma
    13.1.7. Bristol-Myers Squibb Company
    13.1.8. Chimerix Inc.
    13.1.9. Cipla Limited
    13.1.10. Dr. Reddy’s Laboratories Ltd.
    13.1.11. ENYO Pharma SA
    13.1.12. F. Hoffmann-La Roche AG
    13.1.13. Gilead Sciences, Inc.
    13.1.14. GlaxoSmithKline PLC
    13.1.15. Johnson & Johnson
    13.1.16. Merck & Co., Inc.
    13.1.17. Novartis AG
    13.2. Key Product Portfolio
    14. Appendix
    14.1. Discussion Guide
    14.2. License & Pricing
    FIGURE 1. ANTIVIRAL DRUGS MARKET RESEARCH PROCESS
    FIGURE 2. ANTIVIRAL DRUGS MARKET SIZE, 2023 VS 2030
    FIGURE 3. ANTIVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. ANTIVIRAL DRUGS MARKET DYNAMICS
    FIGURE 7. ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
    FIGURE 8. ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
    FIGURE 10. ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2023 VS 2030 (%)
    FIGURE 12. ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 14. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 16. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 18. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 21. ANTIVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 22. ANTIVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023

    $4,749
    $5,749
    $6,749
    $8,749

    Research Assistance

    US: 800.298.5699
    Int'l: +1.240.747.3093
    Live help
    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Other tasks

    Cookie Settings